Today in the Market (1/23/2024)

Good Morning! On Tuesday, the S&P 500 continued its surge to reach new record levels as investors are now paying close attention to daily earnings reports, seeking valuable information about the overall condition of corporate America and the economy.

The S&P 500 and NASDAQ saw gains of 0.29% & 0.43%, while the Dow Jones spent the day in the red and finished under by 0.25%.


It’s earning season once again and to start us off, we have Netflix (NFLX) with fourth-quarter subscriber additions increasing significantly, surpassing its own projected figures. Not only that, it sent the stock up over 8% in after-hours trading!

  • Revenue: $8.83 Billion vs. $8.71 Billion Expected
  • Subscriber Additions: 13.12 Million vs. 9 Million Expected
  • Earnings per Share: $2.11 vs. $2.20 Expected

So what helped the company? According to the earnings statement, the firm saw a roughly 70% rise in ad-tier subscriptions compared to the previous quarter. With that, the current advertising strategy currently represents 40% of all new subscriptions to Netflix in the regions where it is available. Also, we cannot forget the income strategies such as intensifying efforts to combat password sharing, introducing an ad-supported subscription option, and recently increasing prices for certain membership plans.

Don’t get too comfy, though! Netflix acknowledged that the rivalry remains intense, emphasizing the need to enhance their entertainment offerings. While many rivals are reducing their expenditures on content, Netflix is committed to investing in its lineup.



The very recently developed Mosquirix vaccine for malaria, created by GlaxoSmithKline and supported by the World Health Organization (WHO), is currently being administered free of charge to infants aged six months or younger at healthcare centers in Cameroon. According to UNICEF, malaria was responsible for 12% of all childhood fatalities in the nation in 2021.

The good and the bad… Over 600,000 people die each year from malaria, a mosquito-transmitted disease, with Africa accounting for 95% of these fatalities. The vaccination is anticipated to save tens of thousands of lives, yet… The four-dose vaccine is recommended only for children aged up to 17 months. According to health experts, the vaccine has an efficacy rate of around 30% and its effectiveness diminishes after a few months. Additionally, it does not prevent the transmission of the disease so those who have been injected should continue to utilize conventional preventative strategies such as bed nets.

What’s the plan going forward? According to Time, Cameroon aims to immunize around 250,000 children by the end of next year. On top of that, another nineteen African nations plan to begin vaccination programs this year, resulting in an excessive demand that Mosquirix would be unable to meet. However, a second malaria vaccine, recently approved by the WHO, is anticipated to be introduced this year, easing worries about the availability of the vaccine.


Scroll to Top